ROCK Inhibitors for Hematologic Malignancy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematologic malignancies, such as myeloproliferative disease and acute myeloid leukemia, often face issues with toxicity and resistance, necessitating the development of less toxic and more effective therapies that target specific mutations in signaling molecules like KIT, FLT3, and BCR-ABL.
Innovation Solution
Administering Rho kinase (ROCK) inhibitors, such as H-1152, or myosin light chain-specific inhibitory RNA molecules to inhibit ROCK activity in cells expressing oncogenes like ROCK, KIT, FLT3, and BCR-ABL, thereby reducing proliferation and inducing cell death in hematologic malignancy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (chemotherapy, radiotherapy, immunotherapy) are used for hematologic malignancies, then disease treatment is achieved, but toxicity and resistance issues arise
Solution Approach 1:
The patent targets specific signaling molecules (KIT, FLT3, BCR-ABL, ROCK) that are locally mutated or hyperactivated in specific hematologic malignancy subtypes. By focusing on the local molecular abnormalities rather than applying broad systemic therapy, the treatment achieves high efficacy for the specific disease subtype while minimizing toxicity to normal tissues and reducing resistance through targeted mechanism inhibition.
Solution Approach 2:
The patent employs molecularly targeted therapies that change the biochemical parameters of specific signaling pathways. By inhibiting specific kinases (KIT, FLT3, BCR-ABL, ROCK) at the molecular level, the treatment alters the functional state of malignant cells without the broad toxicity of conventional chemotherapy, thereby improving efficacy while reducing harmful effects.
2Adaptability or versatility
If targeted therapies against specific mutations (KIT, FLT3, BCR-ABL) are developed, then treatment specificity is improved, but development complexity increases
Solution Approach 1:
The patent identifies ROCK as an additional target that complements existing targeted therapies against KIT, FLT3, and BCR-ABL. ROCK inhibitors can be used alone or in combination with existing targeted therapies, providing a universal approach that works across multiple hematologic malignancy types and mutation subtypes, thereby enhancing treatment specificity without requiring entirely new therapeutic development pathways.
Data Source
AI summary
The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic malignancies.